Baird raised the firm’s price target on Arcellx (ACLX) to $106 from $77 and keeps an Outperform rating on the shares. The firm said they were Incrementally positive on updated clinical data. The ASH abstracts were published online, including initial data from the registrational IMMagine-1 study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Arcellx price target raised to $106 from $81 at Morgan Stanley
- Arcellx price target raised to $100 from $84 at BofA
- Arcellx price target raised to $95 from $80 at H.C. Wainwright
- Arcellx management to meet virtually with Piper Sandler
- Arcellx to present data for Its Phase 1and iMMagine-1studies to treat RRMM